Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03117491 Completed - Clinical trials for Symptomatic Irreversible Pulpitis

Effect of Inferior Alveolar and Gow-Gates Nerve Block Techniques for Symptomatic Mandibular Molars

Start date: December 1, 2015
Phase: Phase 3
Study type: Interventional

Introduction: to evaluate the efficacy of inferior alveolar nerve block (IANB), Gow-Gates nerve block (GGNB), and their combination in patients with irreversible pulpitis. Methods: One hundred fifty subjects with irreversible pulpitis of a mandibular molar were selected. subjects randomly received two IANB injections or two GGNB injections or their combination of 1.8 mL 2% lidocaine with 1:100,000 epinephrine. Success was specified as no or mild pain on the basis of Heft-Parker visual analogue scale recordings up on the access cavity preparation or initial instrumentation. Data were analyzed by Kruskal-Wallis, and ANOVA tests.

NCT ID: NCT03117400 Completed - Clinical trials for Endoscopic Mucosal Resection

Systematic Description of the Post EMR Defect

Start date: May 2, 2013
Phase:
Study type: Observational

To date there are no available data on the utility of the endoscopic mucosal resection (EMR) defect in stratifying the risk of immediate or delayed adverse outcomes, particularly clinically significant post EMR bleeding (CSPEB). The investigators aimed to analyse the data to determine if any of these EMR defect features allow us to estimate the risk of CSPEB. This will help endoscopists to identify defects with a high risk of adverse outcomes and may translate into improved patient outcomes.

NCT ID: NCT03117335 Completed - Clinical trials for Advanced Non-small Cell Lung Cancer

Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer

Start date: November 10, 2011
Phase: Phase 3
Study type: Interventional

The main object of this trial is to offer treatment of recombinant endostatin ( Sulijia) combined with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer, expecting to improve progression free survival (PFS) , disease control rate(DCR) , objective response rate(ORR) and Overall survival (OS) compared with chemotherapy alone, and evaluate the efficacy and safety of Sulijia.

NCT ID: NCT03117296 Completed - Clinical trials for Transcatheter Aortic Valve Implantation

Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement

PTOTtAVR
Start date: December 3, 2014
Phase:
Study type: Observational [Patient Registry]

Implementation of Physical Therapy (PT) and Occupational Therapy (OT) pathway (initiation of services on Post procedure day #1 and continued daily with focus on education and activity progression) for all patients undergoing a transcatheter aortic value repair procedure began on December 2, 2014. Retrospective data was collected from The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Aortic Valve Replacement Procedures (STS/ACC TVT, trademark) Registry - National database for Transcatherter Aortic Valve Replacement Procedures and included subjects from March 2012 through July 31, 2015. Patients included: s/p tAVR via transfemoral catheter approach, with or without minor intra or post procedure events (GI bleeds, minor access bleeds, afib, etc); Exclusions: Major events including stroke, pacemaker placement, other cardiovascular (CV) repair or surgery required, etc). Future data analysis will extend subjects to December 31, 2015 and annually.

NCT ID: NCT03117088 Completed - Clinical trials for Quality Assurance of Patient Safety

Safe-SCOPE Pilot Study

Safe-SCOPE
Start date: June 1, 2017
Phase: N/A
Study type: Interventional

Study Title Safe- SCOPE Pilot Study Standardized Checklist of Patient Information Exchange Short Title Safe- SCOPE Pilot Study Study Design: Single centre two armed cluster randomised crossover pilot study Study duration: 5 months Objectives: - Influence of standardised checklists on medical/ physician handovers on an Intensive Care Unit -ICU and its influence on patient safety - Satisfaction survey in physicians group Number of patients: All patients treated on OIM during assessment period Checklist Intervention - All physicians working in the department of Intensive Care Medicine and Intermediate Care are informed and enlightened about Safe-SCOPE Pilot Study. After written consent participating physicians will use an online form ISBAR3 Checklist or alternative Checklist for handovers twice a day. - Handover times/schedule: OIM 1,2,3,5, und 6: 7:30 am and 7:30 pm OIM 4 und WEA 1: 7:30 am and 2:00 pm - ISBAR3 Checklist - VICUR Checklist wash- out Phase: - No checklists for one month Efficacy: Patients: - Mortality rate - Duration on ICU - Reuptake on ICU - SOFA Score on admission to ICU, 48h, 72h and 120h after admission - Handover duration per patient - Number of enclosed patients Handover: - Entire handover duration - Interruptions during handover

NCT ID: NCT03116828 Completed - Clinical trials for Epilepsy With Partial On-set Seizures

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Start date: July 7, 2017
Phase: Phase 4
Study type: Interventional

A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures

NCT ID: NCT03116724 Completed - Clinical trials for Patient Safety During Central Venous Catheterization

Direct Measurement of Ideal Depth of Central Line

Start date: April 5, 2017
Phase: N/A
Study type: Interventional

Total of 89 patients undergoing elective cardiac surgery will be enrolled. Right CVC insertion begins at their intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head. After insertion the central venous catheter through the right internal jugular vein and positioning it, the location of the tip of the central venous catheter will be confirmed by TEE.

NCT ID: NCT03116347 Completed - Clinical trials for Primary Immunodeficiency Diseases (PID)

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Start date: May 30, 2017
Phase: Phase 4
Study type: Interventional

The purpose of the study is to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to <18 years) patients with Primary Immunodeficiency Diseases (PIDD)

NCT ID: NCT03116191 Completed - Clinical trials for Nocturia Due to Nocturnal Polyuria

Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Start date: February 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to demonstrate efficacy of SK-1404 against placebo for the treatment of subjects with nocturia due to nocturnal polyuria, during 4 weeks of treatment.

NCT ID: NCT03116152 Completed - Clinical trials for Esophageal Squamous Cell Carcinoma

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

Start date: May 10, 2017
Phase: Phase 2
Study type: Interventional

Efficacy and safety evaluation of IBI308 versus paclitaxel/irinotecan in patients with advanced/metastatic esophageal squamous cell carcinoma after failure of first-line treatment: a randomized, open-label, multicenter, phase 2 study